Results 1 to 10 of about 15,170 (273)

Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic Payload [PDF]

Nanomaterials, 2022
Cyclic arginyl-glycyl-aspartic acid peptide (cRGD) peptides show a high affinity towards αVβ3 integrin, a receptor overexpressed in many cancers. We aimed to combine the versatility of ultrasmall gold nanoparticles (usGNP) with the target selectivity of ...
Enrico Ferrari, Csanad Z Bachrati, Ibon Perera   +2 more
exaly   +18 more sources

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells [PDF]

Frontiers in Pharmacology, 2019
Antibody-drug conjugates (ADCs) are composed of an antibody linked to cytotoxic anticancer payloads. ADCs recognize tumor-specific cell surface antigens and are internalized into lysosomes where proteolytic enzymes release the cytotoxic payloads.
Yurong Lai, Ramaswamy A Iyer, W Griffith Humphreys   +2 more
exaly   +7 more sources

Facile protein conjugation of platinum for light-activated cytotoxic payload release

Chemical Communications, 2021
This platinum anticancer complex can be conjugated to proteins, including antibodies, under mild conditions and activated by visible light, providing a basis for highly selective cancer phototherapy.
Frederik Lermyte, Peter Sadler, Emily P Friar   +2 more
exaly   +5 more sources

Adnectin–drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors [PDF]

Protein Engineering, Design and Selection, 2018
Tumor-specific delivery of cytotoxic agents remains a challenge in cancer therapy. Antibody-drug conjugates (ADC) deliver their payloads to tumor cells that overexpress specific tumor-associated antigens-but the multi-day half-life of ADC leads to high exposure even of normal, antigen-free, tissues and thus contributes to dose-limiting toxicity.
Dasa Lipovsek, Sanjeev Gangwar
exaly   +5 more sources

Payload diversification: a key step in the development of antibody–drug conjugates [PDF]

Journal of Hematology and Oncology, 2023
Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selectivity of monoclonal antibodies with the potency of a payload consisting of cytotoxic agents. For many years microtubule targeting and DNA-
Warren Viricel, Charles Dumontet, Dumontet Charles   +2 more
exaly   +3 more sources

Monomethyl Auristatin E, a Potent Cytotoxic Payload for Development of Antibody-Drug Conjugates against Breast Cancer [PDF]

Novelty in Biomedicine, 2017
Background: Breast cancer is a heterogeneous disease characterized by differential responses to targeted and chemotherapeutic agents. Antibody-drug conjugates are one of the promising strategies for the treatment of breast cancer. Monomethyl auristatin E
Meghdad Abdollahpour-alitappeh, Amir Amanzadeh, Fatemeh Heidarnejad, Mahdi Habibi-Anbouhi, Majid Lotfinia, Sepand Razavi-vakhshourpour, Saeed Jahandideh, Hamid Najminejad, Saeed Balalaie, Mohsen Abolhassani   +9 more
doaj   +4 more sources

DNA-programmed bispecific peptide assemblies for delivering cytotoxic payload to cells expressing EGFR and MET receptors. [PDF]

RSC Chem Biol
Bispecific agents capable of simultaneously targeting two distinct cell surface receptors promise enhanced specificity and efficacy in cancer therapy. Here, we report a strategy for the rapid optimization of compact bispecific agents using nucleic acid hybridization to display peptide ligands for both the Epidermal Growth Factor Receptor (EGFR) and the
Ghosh P, Dinh H, Seitz O.
europepmc   +4 more sources

Antibody-drug conjugates in breast cancer: Progress and future directions [PDF]

Cell Reports Medicine
Summary: Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer, enabling targeted delivery of potent cytotoxic payloads to antigen-expressing tumor cells.
Alexandra Bili Newman, Senthil Damodaran, Funda Meric-Bernstam   +2 more
doaj   +2 more sources

Antibody–Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives [PDF]

Molecules
Antibody–drug conjugates (ADCs) have become an important class of targeted anticancer therapeutics by integrating the tumor selectivity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads through rational linker design.
Guiying Wu, Zhenhai Yuan, Ming Chen, Xuan Tang, Fang Wang, Daizhou Zhang   +5 more
doaj   +2 more sources

Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload. [PDF]

ACS Omega
This study developed a homogeneous ADC via site-specific conjugation of a potent antitumor agent, a camptothecin derivative, to the N-glycan in the Fc domain of an antibody, achieving a drug-to-antibody ratio (DAR) of 4. The resulting glycan-conjugated ADC exhibited improved thermal stability, reduced aggregation, and reduced premature payload release ...
Manabe S, Senga S, Iwamoto S, Yarita H, Takahashi R, Mitani A, Sumiyoshi W, Hoshinoo A, Hiranyakorn M, Kinoshita T, Yoshimura C.   +10 more
europepmc   +3 more sources